Form 4: Amicus Therapeutics Acquired by BioMarin

Chief Development Officer Jeff Castelli reports the disposal of equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Summary

• Jeff Castelli, Chief Development Officer of Amicus Therapeutics, reported the disposal of 427,089 shares of common stock at $14.50 per share.
• Multiple tranches of stock options with exercise prices ranging from $9.41 to $12.11 were cancelled and converted into cash payments.
• The transactions were executed in connection with the completed acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final equity liquidation of an executive following a completed corporate acquisition.

Positives

• The acquisition by BioMarin provides liquidity to the reporting person for all held common stock and vested/accelerated stock options at a set price of $14.50 per share.

Negatives

• The reporting person no longer holds any equity interest in Amicus Therapeutics following the completion of the merger.

Risks

• No ongoing risks are applicable as the issuer has been acquired and the reporting person has divested all holdings.

Future Outlook

Not applicable as the company has been acquired.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of a significant M&A event in the biotechnology sector, reflecting ongoing consolidation trends where larger pharmaceutical entities acquire specialized firms to bolster their pipelines.

Comparison to Industry Standards

• The acquisition price of $14.50 per share represents the final valuation for shareholders in the context of the BioMarin-Amicus merger.
• The acceleration of restricted stock units and options upon a change-in-control event is standard practice in executive compensation agreements within the biopharma industry.

Stakeholder Impact

• Shareholders have received the merger consideration of $14.50 per share.
• The reporting person has exited their position in the company.

Next Steps

• None; the reporting person has zeroed out their holdings in the issuer.

Key Dates

Keywords

Amicus Therapeutics, BioMarin, Merger, Acquisition, Form 4, Insider Transaction, FOLD